Decreased lipidated ApoE-receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes.

Saved in:
Bibliographic Details
Title: Decreased lipidated ApoE-receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes.
Authors: Guo JL; Denali Therapeutics Inc., South San Francisco, CA, USA. Electronic address: guojing84@hotmail.com., Braun D; Denali Therapeutics Inc., South San Francisco, CA, USA., Fitzgerald GA; Denali Therapeutics Inc., South San Francisco, CA, USA., Hsieh YT; Denali Therapeutics Inc., South San Francisco, CA, USA., Rougé L; Denali Therapeutics Inc., South San Francisco, CA, USA., Litvinchuk A; Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA., Steffek M; Denali Therapeutics Inc., South San Francisco, CA, USA., Propson NE; Denali Therapeutics Inc., South San Francisco, CA, USA., Heffner CM; Denali Therapeutics Inc., South San Francisco, CA, USA., Discenza C; Denali Therapeutics Inc., South San Francisco, CA, USA., Han SJ; Denali Therapeutics Inc., South San Francisco, CA, USA., Rana A; Denali Therapeutics Inc., South San Francisco, CA, USA., Skuja LL; Denali Therapeutics Inc., South San Francisco, CA, USA., Lin BQ; Denali Therapeutics Inc., South San Francisco, CA, USA., Sun EW; Denali Therapeutics Inc., South San Francisco, CA, USA., Davis SS; Denali Therapeutics Inc., South San Francisco, CA, USA., Balasundar S; Denali Therapeutics Inc., South San Francisco, CA, USA., Becerra I; Denali Therapeutics Inc., South San Francisco, CA, USA., Dugas JC; Denali Therapeutics Inc., South San Francisco, CA, USA., Ha C; Denali Therapeutics Inc., South San Francisco, CA, USA., Hsiao-Nakamoto J; Denali Therapeutics Inc., South San Francisco, CA, USA., Huang F; Denali Therapeutics Inc., South San Francisco, CA, USA., Jain S; Denali Therapeutics Inc., South San Francisco, CA, USA., Kung JE; Denali Therapeutics Inc., South San Francisco, CA, USA., Liau NPD; Denali Therapeutics Inc., South San Francisco, CA, USA., Mahon CS; Denali Therapeutics Inc., South San Francisco, CA, USA., Nguyen HN; Denali Therapeutics Inc., South San Francisco, CA, USA., Nguyen N; Denali Therapeutics Inc., South San Francisco, CA, USA., Samaddar M; Denali Therapeutics Inc., South San Francisco, CA, USA., Shi Y; Denali Therapeutics Inc., South San Francisco, CA, USA., Tatarakis D; Denali Therapeutics Inc., South San Francisco, CA, USA., Tian Y; Denali Therapeutics Inc., South San Francisco, CA, USA., Zhu Y; Denali Therapeutics Inc., South San Francisco, CA, USA., Suh JH; Denali Therapeutics Inc., South San Francisco, CA, USA., Sandmann T; Denali Therapeutics Inc., South San Francisco, CA, USA., Calvert MEK; Denali Therapeutics Inc., South San Francisco, CA, USA., Arguello A; Denali Therapeutics Inc., South San Francisco, CA, USA., Kane LA; Denali Therapeutics Inc., South San Francisco, CA, USA., Lewcock JW; Denali Therapeutics Inc., South San Francisco, CA, USA., Holtzman DM; Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA., Koth CM; Denali Therapeutics Inc., South San Francisco, CA, USA., Di Paolo G; Denali Therapeutics Inc., South San Francisco, CA, USA. Electronic address: dipaolo@dnli.com.
Source: Cell [Cell] 2025 Jan 09; Vol. 188 (1), pp. 187-206.e26. Date of Electronic Publication: 2024 Nov 11.
Publication Type: Journal Article
Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 0413066 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-4172 (Electronic) Linking ISSN: 00928674 NLM ISO Abbreviation: Cell Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1097-4172
DOI:10.1016/j.cell.2024.10.027